Navigation Links
Sumagen Initiates Clinical Testing of Omnia Biologics Manufactured HIV Vaccine
Date:1/10/2012

ROCKVILLE, Md., Jan. 10, 2012 /PRNewswire/ -- Biologics drug development and manufacturing services provider Omnia Biologics, Inc. (Omnia) (Rockville, MD) today announced that its customer Sumagen, Co., Ltd., (Seoul, S. Korea and London, ON) will begin clinical trials of their revolutionary HIV vaccine design. The Food and Drug Administration approved Phase I clinical trial will begin in January.

The design and testing of the vaccine was spearheaded by Dr. Chil-Yong Kang, a professor at University of Western Ontario's (UWO) medical school. Dr. Dale VanderPutten of Omnia Biologics commented on the development, "To date experimental HIV vaccines have been largely either subunit vaccines or used non-HIV vaccine vectors and have universally failed in the clinic.  Dr. Kang and his team took a page from the successes of polio, flu, rabies and other highly effective vaccines focusing instead on a viral vaccine that is genetically attenuated, irradiated and chemically inactivated."

Omnia participated in the international effort to propel this important advance into the clinic by providing process and assay development services and manufacturing the vaccine under GMP for South Korean biotech company Sumagen Co. Ltd and their academic partner Dr. Kang and UWO.  Preclinical testing has shown the vaccine to be safe and produce strong immune responses.

Steve Hubert, Vice-President of Operations at Omnia commented on his team's success, "It is especially heartening for our team at Omnia to be able to translate this important technology into the clinic as other well established contract manufacturers failed in their attempts to produce the vaccine at clinical scale."

About Omnia Biologics:  (www.omniabiologics.com)

Omnia offers translational medicine services in the areas of process development, assay development, GMP manufacture, and fill-finish for preclinical and clinical programs
'/>"/>

SOURCE Omnia Biologics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Pfizer Initiates Phase 1 Clinical Trial for FVIIa Hemophilia Drug Candidate Developed by Catalyst Biosciences
2. Zimmer Initiates Quarterly Dividend and Announces New Share Repurchase Program
3. Isis Initiates Phase 1 Clinical Study of ISIS-SMNRx in Patients With Spinal Muscular Atrophy
4. Soligenix Initiates Next Generation Anthrax Vaccine Development Program Under Agreement With Harvard University
5. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121 in Combination with Cetuximab and Irinotecan in Patients with Advanced Cancers
6. Regulus Therapeutics Initiates an Orphan and Rare Disease microRNA Therapeutic Effort in Brain Cancer
7. Spring Creek Healthcare Systems Initiates Strategy to Partner and License DelRX Patents
8. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Combination Study of MM-121 and Multiple Anticancer Therapies in Patients with Advanced Solid Tumors
9. BioMarin Initiates Phase 2 Study for GALNS in Patients Under Five Years of Age With MPS IVA
10. Inspiration Biopharmaceuticals Initiates Second Pivotal Clinical Study of Innovative Hemophilia Therapy OBI-1
11. Cara Therapeutics Initiates Phase I Study with Oral Formulation of Novel Peripherally-Acting Kappa Opioid Agonist
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... VILLAGE, Nev. , July 28, 2014 PDL ... that the Company will release its second quarter 2014 financial ... August 11, 2014, after market close. PDL,s management will host ... Eastern Time to discuss the financial results.  A slide presentation ... link on the PDL website. Conference Call Details ...
(Date:7/28/2014)... 28, 2014  ProteinSimple announced today that it has ... new assay allows users to detect all proteins separated ... Western users can analyze proteins without the need for ... changed protein analysis as we know it today. First, the ... - no messy gels, no transfer tanks, no blots, ...
(Date:7/28/2014)... HILDEN , Germany and ... -- , Collaboration aims to ... plasma samples to guide the use of IRESSA  for ... test will build on QIAGEN,s FDA-approved  therascreen   EGFR test ... QIAsymphony family of automated instruments  Project enabled ...
Breaking Medicine Technology:PDL BioPharma to Announce Second Quarter 2014 Financial Results on August 11, 2014 2ProteinSimple Says "Never Run a Gel Again!" 2QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 2QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 3QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 4QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 5QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 6
... The non-profit Midwest Business Group on Health (MBGH) ... national organizations, have launched a health awareness campaign combining the ... people improve and manage health conditions. The Take Control ... will run through the end of the year and into ...
... NATICK, Mass., Oct. 28 Boston Scientific Corporation (NYSE: ... a definitive agreement under which Stryker Corporation will acquire ... billion, payable in cash, of which $1.4 billion is ... following the closing and upon the occurrence of the ...
Cached Medicine Technology:New 'Take Control of Your Health' Education Series to Improve Health of Chicagoans 2Boston Scientific Agrees to Sell Neurovascular Business to Stryker 2Boston Scientific Agrees to Sell Neurovascular Business to Stryker 3Boston Scientific Agrees to Sell Neurovascular Business to Stryker 4
(Date:7/28/2014)... promises to be bigger, better and more interactive than ... Congress Programme Committee. The European Society of Cardiology hosts ... year in August. Record numbers of Hot Line sessions ... is on track to host the largest number of ... extra hot line session has been added this year, ...
(Date:7/28/2014)... UK, have devised a simple blood test that ... or not. , The test will enable ... certain symptoms, saving time and preventing costly and unnecessary ... out. Alternatively, it could be a useful aid for ... that is currently hard to diagnose. , Early ...
(Date:7/28/2014)... 28, 2014 Axiom EPM , ... planning and performance management software for enterprises, today announced ... achieving results that surpassed its record Q1 results, and ... company attributes this growth to increased demand for its ... as the addition of incremental solutions for existing customers. ...
(Date:7/28/2014)... 2014 Freeonlinelifeinsuranceleads.com has released a ... online life insurance quotes. , Comparing life insurance quotes ... life insurance costs. Finding affordable coverage is easier online ... from reliable agencies and displays them on a single ... clients can find cheaper coverage, but they can also ...
(Date:7/28/2014)... Dennis Thompson HealthDay ... The U.S. Supreme Court,s ruling on contraception coverage -- as ... a legal quagmire that might allow companies to deny insurance ... some health care experts say. But other experts counter ... justices ruled 5-4 last month that Hobby Lobby Stores Inc. ...
Breaking Medicine News(10 mins):Health News:ESC Congress 2014 focuses on innovations in cardiology 2Health News:ESC Congress 2014 focuses on innovations in cardiology 3Health News:Potential 'universal' blood test for cancer discovered 2Health News:Potential 'universal' blood test for cancer discovered 3Health News:Axiom EPM Announces Record Second Quarter of 2014 2Health News:Comparing Life Insurance Quotes Online Offers 3 Important Advantages! 2Health News:The 'Hobby Lobby Ruling' and What It Means for U.S. Health Care 2Health News:The 'Hobby Lobby Ruling' and What It Means for U.S. Health Care 3Health News:The 'Hobby Lobby Ruling' and What It Means for U.S. Health Care 4Health News:The 'Hobby Lobby Ruling' and What It Means for U.S. Health Care 5
... who have recurrent fevers are less likely to develop ... National Institutes of Health studied more than 830 children ... fever-related episodes. Researchers defined fever as a temperature of ... evaluated again for allergies when they were between ages ...
... the cardiovascular system in seniors by lowering // blood levels ... ages 70 to 79 who consumed moderate levels of alcohol ... alcohol (more than eight drinks per week), and did not ... the first to focus on the association between alcohol intake ...
... Taiwanese experts , people buying the popular herbal medicine may ... Hypericum, can have mild antidepressant effects, although doctors warn it ... the tablets tested had as much of the active ingredient ... thought to be responsible for the psychoactive effects of St ...
... the use of hormone replacement therapy among breast cancer survivors ... high rate of recurring or new cancers. ,Swedish researchers ... surviving the disease and therefore subject to the same menopausal ... around 1,300 women over five years. After the initial 345 ...
... by eating beef from cattle with mad cow disease ... infected individuals, say researchers according to a recent study. ... the variant form of Creutzfeldt-Jakob disease (vCJD), which has ... with bovine spongiform encephalopathy (BSE), can be transmitted through ...
... potentially fatal disease caused by bacteria. It can attack any ... say beginning in the 1940s with the discovery of antiviral ... States. However, it began to reappear in the 1980s when ... of HIV.However, the incidence of TB has declined since ...
Cached Medicine News:
... two perforations which enable procedure-specific ... single or bilateral configurations to ... has two perforations which enable ... various single or bilateral configurations ...
Unique 2 in 1 design allows simultaneous absorption of excess fluid & protection of flap & hinge, Lint-free PVAmaterial....
Angled 45, 9mm from end, Longer design from bend to tip allows for easier placement of viscoelastic to all meridians, Dome shape, extra smooth tip...
Dome shape, extra smooth tip provides safe insertion through wound & manipulation within the eye. 45, 4.0mm from end...
Medicine Products: